Demonstration of α1A-and α1B-adrenoceptor binding sites in human brain tissue

[1]  J. J. Beckeringh,et al.  α1‐Adrenoceptors: the ability of various agonists and antagonists to discriminate between two distinct [3H]prazosin binding sites , 1989, The Journal of pharmacy and pharmacology.

[2]  G. Gross,et al.  Subclassification of α1‐adrenoceptor recognition sites by urapidil derivatives and other selective antagonists , 1989, British journal of pharmacology.

[3]  G. Gross,et al.  α1-Adrenoceptors of rat myocardium: Comparison of agonist binding and positive inotropic response , 1988, Naunyn-Schmiedeberg's Archives of Pharmacology.

[4]  G. Gross,et al.  5-Methyl-urapidil discriminates between subtypes of the α1-adrenoceptor , 1988 .

[5]  K. Minneman.  Alpha 1-adrenergic receptor subtypes, inositol phosphates, and sources of cell Ca2+. , 1988, Pharmacological reviews.

[6]  P. Abel,et al.  Comparison of alpha 1-adrenergic receptor subtypes distinguished by chlorethylclonidine and WB 4101. , 1988, Molecular pharmacology.

[7]  P. Abel,et al.  α1Adrenoceptor subtypes linked to different mechanisms for increasing intracellular Ca2+ in smooth muscle , 1987, Nature.

[8]  I. Creese,et al.  Characterization of alpha 1-adrenergic receptor subtypes in rat brain: a reevaluation of [3H]WB4104 and [3H]prazosin binding. , 1986, Molecular pharmacology.

[9]  R. Barlow.  Biodata handling with microcomputers , 1983 .

[10]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.